Cover Image

HARDBACK
$59.95



View/Hide Left Panel

tutes of Health is encouraged as one means for fostering more research on the safety of dietary supplement ingredients, especially for high-priority needs identified by FDA when utilizing the framework for safety evaluation.

Recommendation: FDA should ensure that its own National Center for Toxicological Research and the overall Department of Health and Human Services National Toxicology Program are optimally utilized by FDA’s Center for Food Safety and Applied Nutrition for investigation into specific concerns of dietary supplement safety. In addition, FDA and the National Institutes of Health should establish clear guidelines for cooperative efforts on high-priority safety issues related to the use of dietary supplements.

Recommendation: All federally supported research on dietary supplements conducted to assess efficacy should be required to include the collection and reporting of all data related to safety of the ingredient under study.

REFERENCES

Blendon RJ, DesRoches CM, Benson JM, Brodie M, Altman DE. 2001. American’s views on the use and regulation of dietary supplements. Arch Intern Med 161:805–810.


Chang CW, Chu G, Hinz BJ, Grever MD. 2003. Current use of dietary supplementation in patients with age-related macular degeneration. Can J Ophthalmol 38:27–32.


DHHS (U.S. Department of Health and Human Services). 2003a. Dietary Supplement Labels: An Assessment. Office of Inspector General, OEI-01-01-0012. Online. Available at http://oig.hhs.gov/oei/reports/oei-01-01-00121.pdf. Accessed June 25, 2004.

DHHS. 2003b. Dietary Supplement Labels: Key Elements. Office of Inspector General, OEI 01-01-00120. Online. Available at http://oig.hhs.gov/oei/reports/oei-01-01-00120.pdf. Accessed June 25, 2004.

Drazen JM. 2003. Inappropriate advertising of dietary supplements. N Engl J Med 348:777–778.


FDA (Food and Drug Administration). 2002. Letter to Stakeholders. Announcing CAERS—The CFSAN Adverse Event Reporting System. Online. Available at http://www.cfsan.fda.gov/_dms/caersltr.html. Accessed June 25, 2004.

Fontanarosa PB, Drummond R, De Angelis CD. 2003. The need for regulation of dietary supplements—Lessons from Ephedra. J Am Med Assoc 289:1568–1570.


Johnson EM, Wootton JC, Kimzey R, McCullagh L, Wesley R, Byrd DC, Singh KK, Rubino D, Pucino F. 2000. Use of herbal therapies by adults seen in an ambulatory care research setting: An exploratory survey. J Altern Complement Med 6:429–435.


Marcus DM, Grollman AP. 2002. Botanical medicines: The need for new regulations. N Engl J Med 347:2073–2076.

Martin KJ, Jordan TR, Vassar AD, White DB. 2002. Herbal and nonherbal alternative medicine use in Northwest Ohio. Ann Pharmacother 36:1862–1869.


Najm W, Reinsch S, Hoehler F, Tobis J. 2003. Use of complementary and alternative medicine among the ethnic elderly. Altern Ther Health Med 9:50–57.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement